<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>18</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./17/Pharmacology.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='./18/Medicinal_Chemistry.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>18 <a name='18'></a></h1>
	</div>

	<div class='content'>
	<p>
 MEDICINAL CHEMISTRY 
</p>

<h1>ANTIBACTERIAL CHEMOTHERAPEUTICS SUFLOAMIDES,QUINOLONES</h1>

<p>
<img src="./18/pasted_image.png"><br>
→ Red Eye<br>
<ul style='padding-left: 30pt'>
<li>belief that taken up by certain pathogenic bacteria and not by hummans cells</li>
</ul>
→ <i>Sulfanilamide </i><br>
<ul style='padding-left: 30pt'>
<li>colorless</li>
<li>cleavage product fomred by reductive liver metabolism of the admn. dye.</li>
</ul>
</p>

<p>
<img src="./18/pasted_image013.png"><br>
<img src="./18/pasted_image001.png"><br>
→ Compounds used for the treatment of baceterial infections 
</p>

<h1>Mechanism of action of Sulfonamides</h1>

<p>
→ bacteriostatic<br>
→ inhibit enzyme  dihydropteroate synthase<br>
<ul style='padding-left: 30pt'>
<li>needed for biosynthesis of folic acid derivaties [thymine]</li>
<li>which required for DNA</li>
</ul>
→ competing at the active site with<br>
<ul style='padding-left: 30pt'>
<li>(PABA)-[<i>p-aminobenzoic acid]</i></li>
</ul>
→ may also be classified as "antimeabolites"<br>
→ folates are essential for the biosynthesis of thymidine<br>
<ul style='padding-left: 30pt'>
<li>without it bacteria cannot multiply</li>
<li>this inhibition is strongly bacteriostatic → ultimetely bactercidical.</li>
</ul>
→Antimicrobial efficay of sulfonamides can be reserved by<br>
<ul style='padding-left: 30pt'>
<li>adding additional PABA in diet</li>
</ul>
<img src="./18/pasted_image002.png"><br>
<img src="./18/pasted_image003.png">
</p>
<h1>Mechanism of action of Sulfonamides</h1>

<p>
→ bacteriostatic<br>
→ inhibit enzyme  dihydropteroate synthase<br>
<ul style='padding-left: 30pt'>
<li>needed for biosynthesis of folic acid derivaties [thymine]</li>
<li>which required for DNA</li>
</ul>
→ competing at the active site with<br>
<ul style='padding-left: 30pt'>
<li>(PABA)-[<i>p-aminobenzoic acid]</i></li>
</ul>
→ may also be classified as "antimeabolites"<br>
→ folates are essential for the biosynthesis of thymidine<br>
<ul style='padding-left: 30pt'>
<li>without it bacteria cannot multiply</li>
<li>this inhibition is strongly bacteriostatic → ultimetely bactercidical.</li>
</ul>
→Antimicrobial efficay of sulfonamides can be reserved by<br>
<ul style='padding-left: 30pt'>
<li>adding additional PABA in diet</li>
</ul>
</p>

<p>
<img src="./18/pasted_image004.png"><br>
→Sulfadiazine<br>
<ul style='padding-left: 30pt'>
<li>form of its silver salt</li>
<li>topically treatment of burns + against a wide range of bacteria,fungus</li>
</ul>
<img src="./18/pasted_image006.png"><br>
→ sulfisoxazole<br>
<ul style='padding-left: 30pt'>
<li>poor water solubility </li>
<li>led to crystallization in the urine → kideny damage</li>
</ul>
<ul>
<li>because molecules were un-ionized at urinary pH values.</li>
<li>↑ quantities of water to avoid crystalluria.</li>
</ul>
</p>

<p>
→ Sulfonamides <br>
<ul style='padding-left: 30pt'>
<li>deactivated by acetylation at N-4 </li>
<li>glucuronidation of the anilino nitrogen in the liver.</li>
</ul>
</p>

<br>

<p>
→ [STRUCTUAL VARIATION AMONG THE CLINICALY USEFUL SULONAMIDES IS RESTRICTED PRIMARILY TO INSTALLATION OF VARIOUS HETEROCYCLIC AROMATIC SUBSTITUENTS ON THE SULFOAMIDE NITROGEN ]<br>
<img src="./18/pasted_image007.png"><br>
<img src="./18/pasted_image008.png"><br>
→ Suflaetamide<br>
<ul style='padding-left: 30pt'>
<li>used ophthalmically for treatment of eye infenction </li>
</ul>
→ strongly electron-withdrawing character of the aromatmic SO2 group<br>
<ul style='padding-left: 30pt'>
<li>makes the N atom to which it is directly attached "partially electropositive"</li>
</ul>
this in turn → ↑ acidity of the H atoms attached to the N → [slightly acidic]<br>
→ replacement of one of the NH2 hydrogens<br>
<ul style='padding-left: 30pt'>
<li>by an electron-withdrawing hteroaromataic ring</li>
</ul>
<ul>
<li>antimicrobial acitivity +  enhance potency + ↑ water solubility</li>
</ul>
</p>

<h1>Adverse Effects</h1>

<p>
→ rash , phtosensitivity , drug fever<br>
→ <a href="./StJ.html" title="StJ" class="page">StJ</a> syndrome <br>
→ erythema multiforme<br>
<ul style='padding-left: 30pt'>
<li>ulcereation of mucus membranes of the eye , mouth , urethra</li>
</ul>
→ <br>
<img src="./18/pasted_image009.png">
</p>
<h1>TRIMETHROPRIM,</h1>

<p>
→ Inhibitor prevents tetrahydrofolic acid biosynthesis and results in bacteriostasis<br>
→ single agent <br>
<ul style='padding-left: 30pt'>
<li>orall treatment of uncomplicated urinary tract infenction by susceptible bacteria</li>
</ul>
→ 1:5 fixed conc. ratio with the sulfonamide, suflamethoxazole<br>
→ induce bacterial resistance
</p>

<p>
→ resistance is increasingly common<br>
<ul style='padding-left: 30pt'>
<li>pneymococcalk infenctions</li>
<li>single amino acid mutation	 in the dihydrofolate reductase enzyme</li>
</ul>
→ overexpression of dihydrofolate reductase by Staphylococcus aureus has benn reported in resistant strains as well.
</p>

<br>

<p>
<img src="./18/pasted_image010.png"><br>
<img src="./18/pasted_image011.png"><br>
<img src="./18/pasted_image012.png">
</p>
<h1>QUINOLONES:</h1>

<br>

<p>
<img src="./18/pasted_image014.png"><br>
→ synthetic substance<br>
<ul style='padding-left: 30pt'>
<li>N-1 alkylated 3-carboxypyrid-4-one ring fused</li>
<li>to another aromatic ring [carries other substituents]</li>
</ul>
→ first marketed <i>nalidixic acid	[1st gen with cinoxacin]</i>
</p>

<p>
<ul style='padding-left: 30pt'>
<li>classification as 1st gen. due to spectrum of activity and pharmacokientic properties]</li>
</ul>
→ minor urinary tract disinfectants<br>
<ul style='padding-left: 30pt'>
<li>G-</li>
</ul>
→ addition of fluoro group to the 6-position on the basic nucleus<br>
<ul style='padding-left: 30pt'>
<li>greatly increased the biological activity.</li>
</ul>
→ <i>Norfloxacin the first 2nd gene.</i>
</p>

<h1>Quinolones-Structure-activity relationship</h1>

<p>
→essential pharmacophore --. carboxy-4-pyridone nucleus<br>
<ul style='padding-left: 30pt'>
<li>carboxylic acid and ketone → involved in the binding to the DNA/DNA-gyrase enzyme</li>
</ul>
→ reduction of the 2.3-double-bond or the 4-keto group<br>
<ul style='padding-left: 30pt'>
<li>inactivates the molecule</li>
<li>sub at C-2 interferes with enzyme-substrrate complexation</li>
</ul>
→Fluoro sub. at C-6 <br>
<ul style='padding-left: 30pt'>
<li>greatly improves antimicrobial activity [ by ↑ lipophilicity]</li>
</ul>
→ Fluoro gorup at C-8 →<br>
<ul style='padding-left: 30pt'>
<li>further improves absorption and half-life	</li>
<li>also may ↑ drug-induced photosensitivity.</li>
</ul>
→ Hetorocyclic sub. at C-7 <br>
<ul style='padding-left: 30pt'>
<li>improves the spectrum of activity G-</li>
</ul>
→ piperazinyl (as c<i>iprofloxacin</i>)<br>
<ul style='padding-left: 30pt'>
<li>piperazinyl group at C-7 also increase binding to GABA.</li>
<li>as does the addition of bulky groups at the N-1 position (<i>sparfloxacin)</i></li>
</ul>
<div style='padding-left: 60pt'>
— represent the most significant antimicrobial improvement — 
</div>
→ pyrrolidinyl (as <i>moxiflocaxin</i>)
</p>

<p>
→ cyclopropyl sub. at N-1`<br>
<ul style='padding-left: 30pt'>
<li>broaden activity  → against atypical bacteria</li>
</ul>
<ul>
<li><i>Mycoplasma , Clamydia , Legionella  species.</i></li>
</ul>
</p>

<p>
→ Several of the quinolones produce mild to severe photosensitivity <br>
→ A C-8 halogen appears to produce the highest incidence of photosensitivity via singlet oxygen and radical induction.<br>
<ul style='padding-left: 30pt'>
<li><i>Lomerfloxacin → </i>highest potential for producing photosensitivity </li>
</ul>
<ul>
<li>methoxy group at C-8</li>
</ul>
</p>

<br>

<p>
→ chemical incopatibility of these agents<br>
<ul style='padding-left: 30pt'>
<li>ability of these agents to chelate polyalent metmatl ions (Ca+2,Mg+2,Zn+2,Fe+2,Al+3)</li>
<li>results in — ↓ solubility — ↓ drug absorption</li>
</ul>
→ chelation occurs<br>
<ul style='padding-left: 30pt'>
<li>between metals and 3-carboxylic acid and 4-keto groups.</li>
<li>should be admin 4 hours before or 2 hours after the quinolones.</li>
</ul>
<img src="./18/pasted_image022.png">
</p>

<p>
<img src="./18/pasted_image017.png"><br>
<img src="./18/pasted_image018.png"><br>
→ introduction of a third ring to the nucleus gives rise to ofloxacin<br>
<ul style='padding-left: 30pt'>
<li>assymetric carbon at C'3-position</li>
</ul>
→ <i>Levofloxacin</i><br>
<ul style='padding-left: 30pt'>
<li>S-(-) isomer</li>
<li>twice as active as ofloxacin</li>
<li>8 to 128 fold more potent than the R-(+)-isomer</li>
<li>resulting from increased binding to the DNA-gyrase</li>
</ul>
→ 
</p>

<br>
<br>
<br>

<p>
 <img src="./18/pasted_image019.png"><br>
<img src="./18/pasted_image020.png"><br>
<img src="./18/pasted_image021.png">
</p>

<br>
<br>
<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./18/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>37.2kb</td></tr>


			<tr><td><a href='./18/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>72.2kb</td></tr>


			<tr><td><a href='./18/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>53.7kb</td></tr>


			<tr><td><a href='./18/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>92.9kb</td></tr>


			<tr><td><a href='./18/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>55.6kb</td></tr>


			<tr><td><a href='./18/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>91.4kb</td></tr>


			<tr><td><a href='./18/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>159kb</td></tr>


			<tr><td><a href='./18/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>144kb</td></tr>


			<tr><td><a href='./18/pasted_image008.png'>pasted_image008.png</a></td><td>&nbsp;</td><td>95.1kb</td></tr>


			<tr><td><a href='./18/pasted_image009.png'>pasted_image009.png</a></td><td>&nbsp;</td><td>76.6kb</td></tr>


			<tr><td><a href='./18/pasted_image010.png'>pasted_image010.png</a></td><td>&nbsp;</td><td>51.8kb</td></tr>


			<tr><td><a href='./18/pasted_image011.png'>pasted_image011.png</a></td><td>&nbsp;</td><td>57.8kb</td></tr>


			<tr><td><a href='./18/pasted_image012.png'>pasted_image012.png</a></td><td>&nbsp;</td><td>145kb</td></tr>


			<tr><td><a href='./18/pasted_image013.png'>pasted_image013.png</a></td><td>&nbsp;</td><td>44.1kb</td></tr>


			<tr><td><a href='./18/pasted_image014.png'>pasted_image014.png</a></td><td>&nbsp;</td><td>118kb</td></tr>


			<tr><td><a href='./18/pasted_image015.png'>pasted_image015.png</a></td><td>&nbsp;</td><td>66.8kb</td></tr>


			<tr><td><a href='./18/pasted_image016.png'>pasted_image016.png</a></td><td>&nbsp;</td><td>130kb</td></tr>


			<tr><td><a href='./18/pasted_image017.png'>pasted_image017.png</a></td><td>&nbsp;</td><td>84.9kb</td></tr>


			<tr><td><a href='./18/pasted_image018.png'>pasted_image018.png</a></td><td>&nbsp;</td><td>74.8kb</td></tr>


			<tr><td><a href='./18/pasted_image019.png'>pasted_image019.png</a></td><td>&nbsp;</td><td>64.5kb</td></tr>


			<tr><td><a href='./18/pasted_image020.png'>pasted_image020.png</a></td><td>&nbsp;</td><td>89.0kb</td></tr>


			<tr><td><a href='./18/pasted_image021.png'>pasted_image021.png</a></td><td>&nbsp;</td><td>84.9kb</td></tr>


			<tr><td><a href='./18/pasted_image022.png'>pasted_image022.png</a></td><td>&nbsp;</td><td>64.9kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
